Success of CD19-targeted CAR-T-cell therapy is closely related with the nature of CD19: first, CD19 is expressed not only by leukemia cells in patients with B-cell-malignancies, but also by the normal antigen presenting B cells, which can provide additional costimulatory signals for CAR-T-cell activation. This evidence concerns the gene CD19 and leukemia.